Literature DB >> 22706871

Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay.

Shalini Verma1, Wesley O Greaves, Farhad Ravandi, Neelima Reddy, Carlos E Bueso-Ramos, Susan O'Brien, Deborah A Thomas, Hagop Kantarjian, L Jeffrey Medeiros, Rajyalakshmi Luthra, Keyur P Patel.   

Abstract

BRAF protooncogene is an important mediator of cell proliferation and survival signals. BRAF p.V600E mutation was recently described as a molecular marker of hairy cell leukemia (HCL). We developed and validated a pyrosequencing-based approach that covers BRAF mutational hotspots in exons 11 (codon 468) and 15 (codons 595 to 600). The assay detects BRAF mutations at an analytical sensitivity of 5%. We screened 16 unenriched archived bone marrow aspirate samples from patients with a diagnosis of HCL (n = 12) and hairy cell leukemia-variant (HCL-v) (n = 4) using pyrosequencing. BRAF p.V600E mutation was present in all HCL cases and absent in all HCL-v. Our data support the recent finding that BRAF p.V600E mutation is universally present in HCL. Moreover, our pyrosequencing-based assay provides a convenient, rapid, sensitive, and quantitative tool for the detection of BRAF p.V600E mutations in HCL for clinical diagnostic testing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706871      PMCID: PMC5465956          DOI: 10.1309/AJCPL0OPXI9LZITV

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  19 in total

1.  Multiplex Pyrosequencing.

Authors:  Nader Pourmand; Elahe Elahi; Ronald W Davis; Mostafa Ronaghi
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

2.  A sequencing method based on real-time pyrophosphate.

Authors:  M Ronaghi; M Uhlén; P Nyrén
Journal:  Science       Date:  1998-07-17       Impact factor: 47.728

3.  Real-time DNA sequencing using detection of pyrophosphate release.

Authors:  M Ronaghi; S Karamohamed; B Pettersson; M Uhlén; P Nyrén
Journal:  Anal Biochem       Date:  1996-11-01       Impact factor: 3.365

4.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

5.  Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.

Authors:  Punit Chadha; Alfred W Rademaker; Prateek Mendiratta; Benjamin Kim; Darren M Evanchuk; David Hakimian; LoAnn C Peterson; Martin S Tallman
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

6.  High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies.

Authors:  Elaine M Boyd; Anthony J Bench; Mars B van 't Veer; Penny Wright; David M Bloxham; George A Follows; Mike A Scott
Journal:  Br J Haematol       Date:  2011-09-13       Impact factor: 6.998

7.  Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.

Authors:  I W Flinn; K J Kopecky; M K Foucar; D Head; J M Bennett; R Hutchison; W Corbett; P Cassileth; T Habermann; H Golomb; K Rai; E Eisenhauer; F Appelbaum; B Cheson; M R Grever
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

Review 8.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Authors:  P J Roberts; C J Der
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 9.  Therapeutic strategies for inhibiting oncogenic BRAF signaling.

Authors:  Ensar Halilovic; David B Solit
Journal:  Curr Opin Pharmacol       Date:  2008-08-03       Impact factor: 5.547

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  16 in total

1.  Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.

Authors:  Sergio Pina-Oviedo; L Jeffrey Medeiros; Shaoying Li; Joseph D Khoury; Keyur P Patel; Khaled Alayed; R Craig Cason; Christopher J Bowman; C Cameron Yin
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.

Authors:  Rajyalakshmi Luthra; Keyur P Patel; Neelima G Reddy; Varan Haghshenas; Mark J Routbort; Michael A Harmon; Bedia A Barkoh; Rashmi Kanagal-Shamanna; Farhad Ravandi; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Rajesh R Singh
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

3.  Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.

Authors:  Frederic Peyrade; Daniel Re; Clemence Ginet; Lauris Gastaud; Maryline Allegra; Robert Ballotti; Antoine Thyss; Thorsten Zenz; Patrick Auberger; Guillaume Robert
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

4.  Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.

Authors:  Xuan J Wang; Annette Kim; Shaoying Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.

Authors:  Wesley O Greaves; Shalini Verma; Keyur P Patel; Michael A Davies; Bedia A Barkoh; John M Galbincea; Hui Yao; Alexander J Lazar; Kenneth D Aldape; L Jeffrey Medeiros; Rajyalakshmi Luthra
Journal:  J Mol Diagn       Date:  2012-12-27       Impact factor: 5.568

6.  Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing.

Authors:  Davide Vacca; Valeria Cancila; Alessandro Gulino; Giosuè Lo Bosco; Beatrice Belmonte; Arianna Di Napoli; Ada Maria Florena; Claudio Tripodo; Walter Arancio
Journal:  Mol Biol Rep       Date:  2017-12-13       Impact factor: 2.316

7.  Discrepant results for BRAF V600E mutation among different specimens in a case of hairy cell leukemia.

Authors:  Hee-Won Moon; Mina Hur; Sung-Hee Han; Yeo-Min Yun; Sung Yong Kim
Journal:  Ann Lab Med       Date:  2013-06-24       Impact factor: 3.464

Review 8.  Update on the biology and treatment options for hairy cell leukemia.

Authors:  Preetesh Jain; Naveen Pemmaraju; Farhad Ravandi
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 9.  Hairy cell leukemia-new genes, new targets.

Authors:  Robert J Kreitman
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

10.  Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.

Authors:  Guillaume Robert; Valérie Jullian; Arnaud Jacquel; Clémence Ginet; Maeva Dufies; Stephanie Torino; Anaïs Pottier; Frederic Peyrade; Sophie Tartare-Deckert; Geneviève Bourdy; Eric Deharo; Patrick Auberger
Journal:  Oncotarget       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.